PKA

Protein kinase A (PKA) is a cAMP-dependent serine/threonine kinase that functions as a central regulator of cellular phosphorylation networks controlling metabolism, gene transcription, proliferation, differentiation, and apoptosis^[1][2]. In its inactive state, PKA exists as a tetrameric holoenzyme composed of two regulatory subunits and two catalytic subunits, whereas cAMP binding triggers holoenzyme dissociation and releases active catalytic subunits that phosphorylate substrates in the cytoplasm and nucleus^[2][3]. Mechanistically, PKA operates downstream of G protein-coupled receptor signaling and adenylyl cyclase activation, linking extracellular stimuli to rapid intracellular signal transduction and transcriptional responses^[3]. Dysregulation of PKA signaling has been associated with endocrine disorders, neurodevelopmental abnormalities, cardiovascular disease, and tumorigenesis, highlighting its importance in both physiological regulation and disease mechanisms^[1][4][5]. Compared with related catalytic isoforms, the PRKACA-encoded Cα isoform represents the most extensively characterized catalytic subunit and is broadly expressed across tissues, whereas PRKACB-encoded Cβ isoforms display distinct tissue distribution patterns, particularly in the nervous system, and exhibit non-redundant biological functions^[1][6][7]. Increasing evidence indicates that catalytic-subunit specificity is influenced by isoform-dependent subcellular targeting, structural variation, and interactions with anchoring proteins, thereby generating signaling selectivity despite a highly conserved kinase core^[3][6]. For experimental applications, pharmacological PKA inhibitors such as H-89 and peptide inhibitors derived from PKI are widely used to interrogate cAMP-PKA signaling, although isoform-selective targeting remains an important challenge for mechanistic and translational research^[1][4].